133 related articles for article (PubMed ID: 31279153)
1. Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis.
Ribeiro NQ; Santos APN; Emídio ECP; Costa MC; Freitas GJC; Carmo PHF; Silva MF; de Brito CB; de Souza DG; Paixão TA; Santos DA
Int J Antimicrob Agents; 2019 Sep; 54(3):301-308. PubMed ID: 31279153
[TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine reduces amphotericin B deoxycholate nephrotoxicity and improves the outcome of murine cryptococcosis.
Magalhães TFF; Costa MC; Holanda RA; Ferreira GF; Carvalho VSD; Freitas GJC; Ribeiro NQ; Emídio ECP; Carmo PHF; de Brito CB; de Souza DG; Rocha CEV; Paixão TA; de Resende-Stoianoff MA; Santos DA
Med Mycol; 2020 Aug; 58(6):835-844. PubMed ID: 31919505
[TBL] [Abstract][Full Text] [Related]
3. High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.
Santos JRA; Ribeiro NQ; Bastos RW; Holanda RA; Silva LC; Queiroz ER; Santos DA
Sci Rep; 2017 Jul; 7(1):4661. PubMed ID: 28680034
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin as a promising anticryptococcal agent.
Ribeiro NQ; Costa MC; Magalhães TFF; Carneiro HCS; Oliveira LV; Fontes ACL; Santos JRA; Ferreira GF; Araujo GRS; Alves V; Frases S; Paixão TA; de Resende Stoianoff MA; Santos DA
Int J Antimicrob Agents; 2017 Jun; 49(6):695-702. PubMed ID: 28450174
[TBL] [Abstract][Full Text] [Related]
5. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
Silva EG; Paula CR; de Assis Baroni F; Gambale W
Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
[TBL] [Abstract][Full Text] [Related]
6. Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis.
Freitas GJC; Ribeiro NQ; Gouveia-Eufrasio L; Emidio ECP; Guimarães GM; César IC; Paixão TA; Oliveira JBS; Caza M; Kronstad JW; Santos DA
Int J Antimicrob Agents; 2023 Jul; 62(1):106807. PubMed ID: 37030471
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
8. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation.
Sangalli-Leite F; Scorzoni L; Alves de Paula E Silva AC; da Silva JF; de Oliveira HC; de Lacorte Singulani J; Gullo FP; Moraes da Silva R; Regasini LO; Siqueira da Silva DH; da Silva Bolzani V; Fusco-Almeida AM; Soares Mendes-Giannini MJ
Int J Antimicrob Agents; 2016 Nov; 48(5):504-511. PubMed ID: 27742203
[TBL] [Abstract][Full Text] [Related]
9. The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.
Mesa-Arango AC; Trevijano-Contador N; Román E; Sánchez-Fresneda R; Casas C; Herrero E; Argüelles JC; Pla J; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2014 Nov; 58(11):6627-38. PubMed ID: 25155595
[TBL] [Abstract][Full Text] [Related]
10. Randomized, phase 1/2, double-blind pioglitazone repositioning trial combined with antifungals for the treatment of cryptococcal meningitis - PIO study.
Gouveia-Eufrasio L; Ribeiro NQ; Santos JRA; da Costa MC; Emídio ECP; de Freitas GJC; do Carmo PHF; Miranda BA; de Oliveira JCMD; da Silva LMV; Teixeira Leocádio VA; Randi Magalhães VC; Penido I; Pereira LS; Rabelo LF; de Almeida Faria FA; Teixeira Dutra MR; Aspahan M; de Paula L; da Silva DI; Tavares Melo MG; de Andrade Zambelli VA; Gomes Faraco AA; da Costa César I; Alves GP; da Cunha Melo LF; de Aguiar Peres NT; Santos DA
Contemp Clin Trials Commun; 2021 Jun; 22():100745. PubMed ID: 33997457
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.
Clemons KV; Lutz JE; Stevens DA
Antimicrob Agents Chemother; 2001 Mar; 45(3):686-9. PubMed ID: 11181343
[TBL] [Abstract][Full Text] [Related]
12. A subdose of fluconazole alters the virulence of Cryptococcus gattii during murine cryptococcosis and modulates type I interferon expression.
Fontes AC; Bretas Oliveira D; Santos JR; Carneiro HC; Ribeiro NQ; Oliveira LV; Barcellos VA; Paixão TA; Abrahão JS; Resende-Stoianoff MA; Vainstein MH; Santos DA
Med Mycol; 2017 Feb; 55(2):203-212. PubMed ID: 27486215
[TBL] [Abstract][Full Text] [Related]
13. Antifungal therapy in a murine model of disseminated infection by Cryptococcus gattii.
Calvo E; Pastor FJ; Rodríguez MM; Pujol I; Guarro J
Antimicrob Agents Chemother; 2010 Oct; 54(10):4074-7. PubMed ID: 20625150
[TBL] [Abstract][Full Text] [Related]
14. Complexing amphotericin B with gold nanoparticles improves fungal clearance from the brains of mice infected with Cryptococcal neoformans.
Chintalacharuvu KR; Matolek ZA; Pacheco B; Carriera EM; Beenhouwer DO
Med Mycol; 2021 Nov; 59(11):1085-1091. PubMed ID: 34332505
[TBL] [Abstract][Full Text] [Related]
15. Antifungal efficacy of amphotericin B encapsulated fibrin microsphere for treating Cryptococcus neoformans infection in Swiss albino mice.
Khan AA; Jabeen M; Alanazi AM; Khan AA
Braz J Infect Dis; 2016; 20(4):342-8. PubMed ID: 27294976
[TBL] [Abstract][Full Text] [Related]
16. The role of oxidative and nitrosative bursts caused by azoles and amphotericin B against the fungal pathogen Cryptococcus gattii.
Ferreira GF; Baltazar Lde M; Santos JR; Monteiro AS; Fraga LA; Resende-Stoianoff MA; Santos DA
J Antimicrob Chemother; 2013 Aug; 68(8):1801-11. PubMed ID: 23612570
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.
Wu JQ; Shao K; Wang X; Wang RY; Cao YH; Yu YQ; Lou JN; Chen YQ; Zhao HZ; Zhang QQ; Weng XH; Jiang C; Zhu LP
Antimicrob Agents Chemother; 2014 Aug; 58(8):4464-9. PubMed ID: 24867970
[TBL] [Abstract][Full Text] [Related]
18. Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system.
Khan AA; Alanazi AM; Jabeen M; Khan S; Malik A
Eur J Pharm Sci; 2018 Jul; 119():171-178. PubMed ID: 29653177
[TBL] [Abstract][Full Text] [Related]
19. Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii.
Batista-Duharte A; Lastre M; Romeu B; Portuondo DL; Téllez-Martínez D; Manente FA; Pérez O; Carlos IZ
Int Immunopharmacol; 2016 Nov; 40():277-287. PubMed ID: 27639705
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intrathecal administration of liposomal amphotericin B combined with voriconazole in a murine model of cryptococcal meningitis.
Gazzoni AF; Capilla J; Mayayo E; Guarro J
Int J Antimicrob Agents; 2012 Mar; 39(3):223-7. PubMed ID: 22226648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
